Keyphrases
Receptor Subtypes
100%
Neurotensin Receptor
100%
Locomotor Activity
100%
PD149163
100%
NTS1
75%
Hyperactivity
37%
Nucleus Accumbens
37%
Neurotensin
37%
Microinjection
25%
Brain Regions
25%
Locomotion
25%
Medial Prefrontal Cortex (mPFC)
25%
Receptor-mediated
12%
Systemic Administration
12%
SKF81297
12%
Behavioral Effects
12%
Specific Mechanisms
12%
Therapeutic Window
12%
Intracerebroventricular Administration
12%
Hyperlocomotion
12%
Movement Disorders
12%
Locomotor
12%
Subtype-specific
12%
Dopaminergic Signaling
12%
Dopamine Receptor
12%
Home Cage
12%
D2R Agonists
12%
Bromocriptine
12%
Targeted Therapy
12%
Novel Environment
12%
Pharmacological Attributes
12%
C57BL
12%
Neuroscience
Neurotensin Receptor
100%
N2 (2,6 Diaminohexyl)lysylprolyltryptophyl 3 Methylvalylleucine Ethyl Ester
100%
Locomotor Activity
100%
Agonist
37%
Nucleus Accumbens
37%
Hyperactivity
37%
Neurotensin
37%
Prefrontal Cortex
25%
Locomotion
25%
Receptor Subtype
12%
Stereotypic Movement Disorder
12%
Behavioral Effect
12%
Bromocriptine
12%
Dopaminergic
12%
Dopamine Receptor
12%
Pharmacology, Toxicology and Pharmaceutical Science
N2 (2,6 Diaminohexyl)lysylprolyltryptophyl 3 Methylvalylleucine Ethyl Ester
100%
Neurotensin Receptor
100%
Hyperactivity
37%
Neurotensin
37%
Systemic Administration
12%
Dopamine Receptor
12%
Behavioral Effect
12%
Bromocriptine
12%
C57BL 6 Mouse
12%
Motor Dysfunction
12%
Therapeutic Window
12%
Dopamine Receptor Stimulating Agent
12%
Receptor Subtype
12%